Evidence map›Paper›PMID 36547252›Full record

ArticleEpigenomes2022

Promoter-Adjacent DNA Hypermethylation Can Downmodulate Gene Expression:

Kenneth C Ehrlich, Michelle Lacey, Carl Baribault, Sagnik Sen, Pierre Olivier Esteve, Sriharsa Pradhan, Melanie Ehrlich

Open access · diamondAbstract read
In one paragraph

Article in Epigenomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kenneth C EhrlichBiomedical Informatics and Genomics Center, Tulane University Health Sciences Center, New Orleans, LA 70112, USA.
Michelle LaceyDepartment of Mathematics, Tulane University, New Orleans, LA 70118, USA.
Carl BaribaultInformation Technology, Tulane University, New Orleans, LA 70118, USA.
Sagnik SenGenome Biology Division, New England Biolabs, Ipswich, MA 01938, USA.ORCID 0000-0002-3362-1677
Pierre Olivier EsteveGenome Biology Division, New England Biolabs, Ipswich, MA 01938, USA.
Sriharsa PradhanGenome Biology Division, New England Biolabs, Ipswich, MA 01938, USA.
Melanie EhrlichBiomedical Informatics and Genomics Center, Tulane University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0002-8187-4476
Tulane University · USNew England Biolabs (United States) · US

Funding

NIH HHS NS04885
6 · The paper itself

Abstract

TBX15, which encodes a differentiation-related transcription factor, displays promoter-adjacent DNA hypermethylation in myoblasts and skeletal muscle (psoas) that is absent from non-expressing cells in other lineages. By whole-genome bisulfite sequencing (WGBS) and enzymatic methyl-seq (EM-seq), these hypermethylated regions were found to border both sides of a constitutively unmethylated promoter. To understand the functionality of this DNA hypermethylation, we cloned the differentially methylated sequences (DMRs) in CpG-free reporter vectors and tested them for promoter or enhancer activity upon transient transfection. These cloned regions exhibited strong promoter activity and, when placed upstream of a weak promoter, strong enhancer activity specifically in myoblast host cells. In vitro CpG methylation targeted to the DMR sequences in the plasmids resulted in 86−100% loss of promoter or enhancer activity, depending on the insert sequence. These results as well as chromatin epigenetic and transcription profiles for this gene in various cell types support the hypothesis that DNA hypermethylation immediately upstream and downstream of the unmethylated promoter region suppresses enhancer/extended promoter activity, thereby downmodulating, but not silencing, expression in myoblasts and certain kinds of skeletal muscle. This promoter-border hypermethylation was not found in cell types with a silent TBX15 gene, and these cells, instead, exhibit repressive chromatin in and around the promoter. TBX18, TBX2, TBX3 and TBX1 display TBX15-like hypermethylated DMRs at their promoter borders and preferential expression in myoblasts. Therefore, promoter-adjacent DNA hypermethylation for downmodulating transcription to prevent overexpression may be used more frequently for transcription regulation than currently appreciated.

Indexed as

DMRsDNA hypermethylationEM-seqenhancersmyoblastsskeletal muscleT-box transcription factorsTBX15transfectionwhole-genome bisulfite sequencing

Identifiers

PMID36547252
PMCPMC9778270
OpenAlexW4312000415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.